TY - JOUR AU - Mueller, R. L. AU - Scheidt, S. PY - 1994 DA - 1994// TI - History of drugs for thrombotic disease. Discovery, development, and directions for the future JO - Circulation. VL - 89 UR - https://doi.org/10.1161/01.CIR.89.1.432 DO - 10.1161/01.CIR.89.1.432 ID - Mueller1994 ER - TY - JOUR AU - Robert, F. PY - 2010 DA - 2010// TI - The potential benefits of low-molecular-weight heparins in cancer patients JO - J Hematol Oncol. VL - 3 UR - https://doi.org/10.1186/1756-8722-3-3 DO - 10.1186/1756-8722-3-3 ID - Robert2010 ER - TY - JOUR AU - Redondo, S. AU - Martinez, M. P. AU - Ramajo, M. AU - Navarro-Dorado, J. AU - Barez, A. AU - Tejerina, T. PY - 2011 DA - 2011// TI - Pharmacological basis and clinical evidence of dabigatran therapy JO - J Hematol Oncol. VL - 4 UR - https://doi.org/10.1186/1756-8722-4-53 DO - 10.1186/1756-8722-4-53 ID - Redondo2011 ER - TY - JOUR AU - Arepally, G. M. AU - Ortel, T. L. PY - 2015 DA - 2015// TI - Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin? JO - Annu Rev Med. VL - 66 UR - https://doi.org/10.1146/annurev-med-051113-024633 DO - 10.1146/annurev-med-051113-024633 ID - Arepally2015 ER - TY - JOUR AU - Mega, J. L. AU - Simon, T. PY - 2015 DA - 2015// TI - Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments JO - Lancet. VL - 386 UR - https://doi.org/10.1016/S0140-6736(15)60243-4 DO - 10.1016/S0140-6736(15)60243-4 ID - Mega2015 ER - TY - JOUR AU - Buller, H. AU - Investigators, H. -. V. PY - 2013 DA - 2013// TI - Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism JO - N Engl J Med. VL - 369 UR - https://doi.org/10.1056/NEJMoa1306638 DO - 10.1056/NEJMoa1306638 ID - Buller2013 ER - TY - JOUR AU - Giugliano, R. P. AU - Ruff, C. T. AU - Braunwald, E. AU - Murphy, S. A. AU - Wiviott, S. D. AU - Halperin, J. L. PY - 2013 DA - 2013// TI - Edoxaban versus warfarin in patients with atrial fibrillation JO - N Engl J Med. VL - 369 UR - https://doi.org/10.1056/NEJMoa1310907 DO - 10.1056/NEJMoa1310907 ID - Giugliano2013 ER - TY - JOUR AU - Greinacher, A. AU - Thiele, T. AU - Selleng, K. PY - 2015 DA - 2015// TI - Reversal of anticoagulants: an overview of current developments JO - Thromb Haemost. VL - 113 UR - https://doi.org/10.1160/TH14-11-0982 DO - 10.1160/TH14-11-0982 ID - Greinacher2015 ER - TY - JOUR AU - Siegal, D. M. AU - Garcia, D. A. AU - Crowther, M. A. PY - 2014 DA - 2014// TI - How I treat target-specific oral anticoagulant—associated bleeding JO - Blood. VL - 123 UR - https://doi.org/10.1182/blood-2013-09-529784 DO - 10.1182/blood-2013-09-529784 ID - Siegal2014 ER - TY - JOUR AU - Bauer, K. A. PY - 2015 DA - 2015// TI - Targeted anti-anticoagulants JO - N Engl J Med. VL - 373 UR - https://doi.org/10.1056/NEJMe1506600 DO - 10.1056/NEJMe1506600 ID - Bauer2015 ER - TY - JOUR AU - Es, N. AU - Coppens, M. AU - Schulman, S. AU - Middeldorp, S. AU - Büller, H. R. PY - 2014 DA - 2014// TI - Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials JO - Blood. VL - 124 UR - https://doi.org/10.1182/blood-2014-04-571232 DO - 10.1182/blood-2014-04-571232 ID - Es2014 ER - TY - JOUR AU - Hylek, E. M. AU - Held, C. AU - Alexander, J. H. AU - Lopes, R. D. AU - Caterina, R. AU - Wojdyla, D. M. PY - 2014 DA - 2014// TI - Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE Trial (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation): predictors, characteristics, and clinical outcomes JO - J Am Coll Cardiol. VL - 63 UR - https://doi.org/10.1016/j.jacc.2014.02.549 DO - 10.1016/j.jacc.2014.02.549 ID - Hylek2014 ER - TY - JOUR AU - Ruff, C. T. AU - Giugliano, R. P. AU - Braunwald, E. AU - Hoffman, E. B. AU - Deenadayalu, N. AU - Ezekowitz, M. D. PY - 2014 DA - 2014// TI - Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials JO - Lancet. VL - 383 UR - https://doi.org/10.1016/S0140-6736(13)62343-0 DO - 10.1016/S0140-6736(13)62343-0 ID - Ruff2014 ER - TY - STD TI - Kham NM, Song M. Spontaneous, life-threatening hemorrhagic cardiac tamponade secondary to rivaroxaban. Am J Ther. 2015;22:PMID 26035030. ID - ref14 ER - TY - JOUR AU - Halvorsen, S. AU - Atar, D. AU - Yang, H. AU - Caterina, R. AU - Erol, C. AU - Garcia, D. PY - 2014 DA - 2014// TI - Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial JO - Eur Heart J. VL - 35 UR - https://doi.org/10.1093/eurheartj/ehu046 DO - 10.1093/eurheartj/ehu046 ID - Halvorsen2014 ER - TY - JOUR AU - Honickel, M. AU - Treutler, S. AU - Ryn, J. AU - Tillmann, S. AU - Rossaint, R. AU - Grottke, O. PY - 2015 DA - 2015// TI - Reversal of dabigatran anticoagulation ex vivo: porcine study comparing prothrombin complex concentrates and idarucizumab JO - Thromb Haemost. VL - 113 UR - https://doi.org/10.1160/TH14-08-0712 DO - 10.1160/TH14-08-0712 ID - Honickel2015 ER - TY - JOUR AU - Hankey, G. J. AU - Eikelboom, J. W. PY - 2011 DA - 2011// TI - Dabigatran etexilate: a new oral thrombin inhibitor JO - Circulation. VL - 123 UR - https://doi.org/10.1161/CIRCULATIONAHA.110.004424 DO - 10.1161/CIRCULATIONAHA.110.004424 ID - Hankey2011 ER - TY - JOUR AU - Connolly, S. J. AU - Ezekowitz, M. D. AU - Yusuf, S. AU - Eikelboom, J. AU - Oldgren, J. AU - Parekh, A. PY - 2009 DA - 2009// TI - Dabigatran versus warfarin in patients with atrial fibrillation JO - N Engl J Med. VL - 361 UR - https://doi.org/10.1056/NEJMoa0905561 DO - 10.1056/NEJMoa0905561 ID - Connolly2009 ER - TY - JOUR AU - Hernandez, I. AU - Baik, S. H. AU - Piñera, A. AU - Zhang, Y. PY - 2015 DA - 2015// TI - Risk of bleeding with dabigatran in atrial fibrillation JO - JAMA Intern Med. VL - 175 UR - https://doi.org/10.1001/jamainternmed.2014.5398 DO - 10.1001/jamainternmed.2014.5398 ID - Hernandez2015 ER - TY - JOUR AU - Warkentin, T. E. AU - Margetts, P. AU - Connolly, S. J. AU - Lamy, A. AU - Ricci, C. AU - Eikelboom, J. W. PY - 2012 DA - 2012// TI - Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding JO - Blood. VL - 119 UR - https://doi.org/10.1182/blood-2011-11-393587 DO - 10.1182/blood-2011-11-393587 ID - Warkentin2012 ER - TY - JOUR AU - Paul, S. AU - Hamouda, D. AU - Prashar, R. AU - Mbaso, C. AU - Khan, A. AU - Ali, A. PY - 2015 DA - 2015// TI - Management of dabigatran-induced bleeding with continuous venovenous hemodialysis JO - Int J Hematol. VL - 101 UR - https://doi.org/10.1007/s12185-015-1739-7 DO - 10.1007/s12185-015-1739-7 ID - Paul2015 ER - TY - JOUR AU - Schiele, F. AU - Ryn, J. AU - Canada, K. AU - Newsome, C. AU - Sepulveda, E. AU - Park, J. PY - 2013 DA - 2013// TI - A specific antidote for dabigatran: functional and structural characterization JO - Blood. VL - 121 UR - https://doi.org/10.1182/blood-2012-11-468207 DO - 10.1182/blood-2012-11-468207 ID - Schiele2013 ER - TY - JOUR AU - Glund, S. AU - Moschetti, V. AU - Norris, S. AU - Stangier, J. AU - Schmohl, M. AU - Ryn, J. PY - 2015 DA - 2015// TI - A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran JO - Thromb Haemost. VL - 113 UR - https://doi.org/10.1160/TH14-12-1080 DO - 10.1160/TH14-12-1080 ID - Glund2015 ER - TY - STD TI - Pinto I, Giri A, Arshad U, Gajra A. New Oral Anticoagulants and Their Reversal. Curr Drug Saf. 2015;10:PMID 25877809. ID - ref24 ER - TY - JOUR AU - Pollack, C. V. PY - 2012 DA - 2012// TI - New oral anticoagulants in the ED setting: a review JO - Am J Emerg Med. VL - 30 UR - https://doi.org/10.1016/j.ajem.2012.04.005 DO - 10.1016/j.ajem.2012.04.005 ID - Pollack2012 ER - TY - STD TI - Pollack CV. Coagulation assessment with the new generation of oral anticoagulants. Emerg Med J. 2015;32. doi:10.1136/emermed-2015-204891. ID - ref26 ER - TY - JOUR AU - Pollack, C. V. AU - Reilly, P. A. AU - Bernstein, R. AU - Dubiel, R. AU - Eikelboom, J. AU - Glund, S. PY - 2015 DA - 2015// TI - Design and rationale for RE-VERSE AD: a phase 3 study of idarucizumab, a specific reversal agent for dabigatran JO - Thromb Haemost. VL - 114 UR - https://doi.org/10.1160/TH15-03-0192 DO - 10.1160/TH15-03-0192 ID - Pollack2015 ER - TY - JOUR AU - Pollack, C. V. AU - Reilly, P. A. AU - Eikelboom, J. AU - Glund, S. AU - Verhamme, P. AU - Bernstein, R. A. PY - 2015 DA - 2015// TI - Idarucizumab for dabigatran reversal JO - N Engl J Med. VL - 373 UR - https://doi.org/10.1056/NEJMoa1502000 DO - 10.1056/NEJMoa1502000 ID - Pollack2015 ER - TY - JOUR AU - Beyer-Westendorf, J. AU - Förster, K. AU - Pannach, S. AU - Ebertz, F. AU - Gelbricht, V. AU - Thieme, C. PY - 2014 DA - 2014// TI - Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry JO - Blood. VL - 124 UR - https://doi.org/10.1182/blood-2014-03-563577 DO - 10.1182/blood-2014-03-563577 ID - Beyer-Westendorf2014 ER - TY - JOUR AU - Gomez-Outes, A. AU - Suarez-Gea, M. L. AU - Lecumberri, R. AU - Terleira-Fernandez, A. I. AU - Vargas-Castrillon, E. PY - 2014 DA - 2014// TI - Specific antidotes in development for reversal of novel anticoagulants: a review JO - Recent Pat Cardiovasc Drug Discov. VL - 9 UR - https://doi.org/10.2174/1574890109666141205132531 DO - 10.2174/1574890109666141205132531 ID - Gomez-Outes2014 ER - TY - JOUR AU - Lu, G. AU - DeGuzman, F. R. AU - Hollenbach, S. J. AU - Karbarz, M. J. AU - Abe, K. AU - Lee, G. PY - 2013 DA - 2013// TI - A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa JO - Nat Med. VL - 19 UR - https://doi.org/10.1038/nm.3102 DO - 10.1038/nm.3102 ID - Lu2013 ER - TY - STD TI - Crowther M KM, Lorenz T, Mathur V, Lu G, Hutchaleelaha A, et al. A phase 2 randomized, double-blind, placebo-controlled trial of PRT064445, a novel, universal antidote for direct and indirect factor Xa inhibitors. J Thromb Haemost. 2013;11(Suppl 2): AS20.1. ID - ref32 ER - TY - STD TI - Crowther M LG, Lu G, Conley PB, Castillo J, Hollenbach S, et al. Reversal of enoxaparin-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for direct and indirect FXa inhibitors—a phase 2 randomized, double-blind, placebo- controlled trial. J Thromb Haemost. 2014;12(Suppl 1): COA01 (abstract). ID - ref33 ER - TY - STD TI - Crowther M LG, Conley P, Hollenbach S, Castillo J, Lawrence, J, et al. Sustained reversal of apixaban anticoagulation with andexanet alfa using a bolus plus infusion regimen in a phase 2 placebo controlled trial. Eur Heart J 2014;35(Suppl.1): P738 (abstract). ID - ref34 ER - TY - JOUR AU - Crowther, M. M. V. AU - Kitt, M. AU - Lu, G. AU - Conley, P. B. AU - Hollenbach, S. PY - 2013 DA - 2013// TI - A phase 2 randomized, double blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for Fxa inhibitors JO - Blood. VL - 122 ID - Crowther2013 ER - TY - JOUR AU - Bakhru, S. AU - Laulicht, B. AU - Jiang, X. AU - Chen, L. AU - Pan, D. AU - Grosso, M. PY - 2013 DA - 2013// TI - PER977: a synthetic small molecule which reverses over-dosage and bleeding by the new oral anticoagulants JO - Ciuculation. VL - 128 ID - Bakhru2013 ER - TY - JOUR AU - Ansell, J. E. AU - Bakhru, S. H. AU - Laulicht, B. E. AU - Steiner, S. S. AU - Grosso, M. AU - Brown, K. PY - 2014 DA - 2014// TI - Use of PER977 to reverse the anticoagulant effect of edoxaban JO - N Engl J Med. VL - 371 UR - https://doi.org/10.1056/NEJMc1411800 DO - 10.1056/NEJMc1411800 ID - Ansell2014 ER -